SGR 3907
Alternative Names: SGR-3907Latest Information Update: 04 May 2026
At a glance
- Originator Schrodinger
- Class Anti-inflammatories; Cardiovascular therapies
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cardiovascular disorders; Inflammation; Metabolic disorders
Most Recent Events
- 24 Apr 2026 Early research in Cardiovascular disorders in USA (unspecified route) prior to April 2026 (Schrodinger Pipeline, April 2026)
- 24 Apr 2026 Early research in Metabolic disorders in USA (unspecified route) prior to April 2026 (Schrodinger Pipeline, April 2026)
- 03 Oct 2023 Early research in Inflammation in USA (unspecified route) prior to October 2023 (Schrodinger pipeline, October 2023)